中华小儿外科杂志
中華小兒外科雜誌
중화소인외과잡지
CHINESE JOURNAL OF PEDIATRIC SURGERY
2010年
8期
565-569
,共5页
刘鑫%王常林%牛之彬%杨屹
劉鑫%王常林%牛之彬%楊屹
류흠%왕상림%우지빈%양흘
肾母细胞瘤%血管内皮生长因子%受体,血管内皮生长因子
腎母細胞瘤%血管內皮生長因子%受體,血管內皮生長因子
신모세포류%혈관내피생장인자%수체,혈관내피생장인자
Nephroblastoma%Vascular endothelial growth factor%Receptors,vascular endothelial growth factor
目的 探讨肾母细胞瘤组织中血管内皮生长因子(VEGF)及其受体(Flk-1)的表达和肿瘤微血管密度(MVD)的临床意义.方法 应用免疫组织化学(SABC)法检测33例肾母细胞瘤、瘤旁组织和6例正常肾组织中VEGF、Flk-1表达和MVD计数.观察并分析三个指标之间的相关性,同时分析其临床意义.结果 33例肿瘤组织VEGF阳性表达率81.8%,Flk-1阳性表达率69.7%,瘤旁组织VEGF阳性表达率9.1%,Flk-1阳性表达率6.1%,6例正常肾组织VEGF及Flk-1均为阴性表达,三者之问差异具有统计学意义.肿瘤组织MVD值29.7±12.4,瘤旁组织MVD值10.3±9.6,正常肾组织MVD值9.8±2.3.肿瘤组织的血管密度与后二者比较差异具有统计学意义.VEGF表达与Flk-1、MVD计数正相关,Flk-1与MVD表达正相关,VEGF、Flk-1表达在不同临床分期,及转归之问均具有显著性差异.结论 肾母细胞瘤中VEGF及其受体Flk-1呈高表达,血管生成增多,VEGF、Flk-1表达与MVD密切相关,提示VEGF及其受体Flk-1参与肾母细胞瘤的血管形成过程,促进血管生成,与预后相关.
目的 探討腎母細胞瘤組織中血管內皮生長因子(VEGF)及其受體(Flk-1)的錶達和腫瘤微血管密度(MVD)的臨床意義.方法 應用免疫組織化學(SABC)法檢測33例腎母細胞瘤、瘤徬組織和6例正常腎組織中VEGF、Flk-1錶達和MVD計數.觀察併分析三箇指標之間的相關性,同時分析其臨床意義.結果 33例腫瘤組織VEGF暘性錶達率81.8%,Flk-1暘性錶達率69.7%,瘤徬組織VEGF暘性錶達率9.1%,Flk-1暘性錶達率6.1%,6例正常腎組織VEGF及Flk-1均為陰性錶達,三者之問差異具有統計學意義.腫瘤組織MVD值29.7±12.4,瘤徬組織MVD值10.3±9.6,正常腎組織MVD值9.8±2.3.腫瘤組織的血管密度與後二者比較差異具有統計學意義.VEGF錶達與Flk-1、MVD計數正相關,Flk-1與MVD錶達正相關,VEGF、Flk-1錶達在不同臨床分期,及轉歸之問均具有顯著性差異.結論 腎母細胞瘤中VEGF及其受體Flk-1呈高錶達,血管生成增多,VEGF、Flk-1錶達與MVD密切相關,提示VEGF及其受體Flk-1參與腎母細胞瘤的血管形成過程,促進血管生成,與預後相關.
목적 탐토신모세포류조직중혈관내피생장인자(VEGF)급기수체(Flk-1)적표체화종류미혈관밀도(MVD)적림상의의.방법 응용면역조직화학(SABC)법검측33례신모세포류、류방조직화6례정상신조직중VEGF、Flk-1표체화MVD계수.관찰병분석삼개지표지간적상관성,동시분석기림상의의.결과 33례종류조직VEGF양성표체솔81.8%,Flk-1양성표체솔69.7%,류방조직VEGF양성표체솔9.1%,Flk-1양성표체솔6.1%,6례정상신조직VEGF급Flk-1균위음성표체,삼자지문차이구유통계학의의.종류조직MVD치29.7±12.4,류방조직MVD치10.3±9.6,정상신조직MVD치9.8±2.3.종류조직적혈관밀도여후이자비교차이구유통계학의의.VEGF표체여Flk-1、MVD계수정상관,Flk-1여MVD표체정상관,VEGF、Flk-1표체재불동림상분기,급전귀지문균구유현저성차이.결론 신모세포류중VEGF급기수체Flk-1정고표체,혈관생성증다,VEGF、Flk-1표체여MVD밀절상관,제시VEGF급기수체Flk-1삼여신모세포류적혈관형성과정,촉진혈관생성,여예후상관.
Objective To investigate the expression and clinical significance of vascular endothelial growth factor (VEGF) and its receptor Flk-1 in nephroblastoma. To assess whether tumor microvessel density (MVD) immunoreactivity, determined by the CD34 antigen, is related to the expression of VEGF and Flt-1. Methods Immunohistochemical staining (SABC) was used to examine MVD and the expression of VEGF, Flk-1 in 33 nephroblastoma tissues, 33 paracancer renal tissues and 6 normal kidney tissues. The relation between the expressions of VEGF, Flk-1 and MVD was analyzed in different clinical stage and pathology type, Patients were treated preoperatively with chemotherapy and mean follow up was 34 months. Results The positive rates of VEGF and Flk-1 in nephroblastoma tissues were 81.8% and 69.7%, the positive rates of VEGF and Flk-1 in paracancer renal tissues were 9.1% and 6.1%, the expressions of VEGF and Flk-1 were negative in all normal kidney. The differences between the three groups were statistically significant (P＜0.05). In nephroblastoma tissues,the expression of VEGF correlated to both Flt-1 and MVD (P＜0.05), and the expression of Flt-1 correlated to MVD (P＜0.05). In addition, the expressions of VEGF and Flk-1 were increased in clinical stage Ⅲ and poor prognosis. Conclusions These results indicate that VEGF and Flk-1 may play an important role in nephroblastoma angiogenesis. Increased expression of VEGF and Flk-1 in nephroblastoma correlated with tumor stage, clinical progression and tumor related death. VEGF and Flk-1 protein expression are closely related to MVD and seem to be a important predictor for poor prognosis in treated patients with nephroblastoma.
